Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

K-V Pharma Settlement With Hologic Approved

On Friday, K-V Pharmaceutical (UNKNOWN: KVPHQ.DL  ) announced that the U.S. Bankruptcy Court for the Southern District of New York has approved the company's settlement agreement with Hologic (NASDAQ: HOLX  ) , resolving the company's dispute over the Makena drug for mitigating the risk of premature delivery. The court has also permitted K-V to enter into a debtor-in-possession financing arrangement that will be used, in part, to fund the settlement.

K-V noted that the settlement with Hologic resolves all disputes between the two parties, confirms K-V's ownership of the drug, and is a key step in K-V's progress toward emerging from Chapter 11 bankruptcy.

Shares of K-V, now trading on the over-the-counter market, dropped one penny (17.5%) on the news to $0.07. Shares of Hologic declined 0.7% to $19.98.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2172097, ~/Articles/ArticleHandler.aspx, 5/22/2015 10:55:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...